CEACAM5 and non-small cell lung carcinoma: Most promising data came from the non-squamous NSCLC cohort [70], where a high antitumor activity was shown particularly in patients with high expression of CEACAM5 (≥ 50%; ORR 20.3%, SD 42.2%), while responses were reduced in moderate expressors (1–49%; ORR 7.1%).